ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie (ABBV) closed the most recent trading day at $209.17, moving -0.4% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.77%. At the same time, ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Wall Street analysts are moderately bullish on ABBV’s prospects. The stock has a consensus “Moderate Buy” rating from the 25 analysts covering it, and the mean price target of $207.20 ...

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same ...

But the move higher after this announcement just continues the bullish pattern in place with ABBV stock, which has been up more than 19% since the start of the year. Analyst sentiment suggests the ...

AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients AbbVie's Elahere maintains strong efficacy in the Phase 3 ...

With the shares kicking off 2025 with a solid 8% gain year to date, some investors may wonder -- can the rally keep going, and is AbbVie stock a buy right now? Here's what you need to know.